Week 3 Flashcards

1
Q

how to reduce medication errors

A

reducing the use of abbreviations
electronically written rather than handwritten
encouraging active participation of patients regarding their health

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

types of non-adherance

A

failure to take medication, to take correct dose, taking for the wrong reasons, incorrect timing of doses, taking other medication resulting in interaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

factors affecting adherence

A

patient characteristics, treatment setting, medication characteristics, clinical features of illness, clinical expertise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

prevention of adherence problems

A

identify at risk patients
treatment planning
appropriate explanation to patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what affects patients understanding?

A

intellect of patients
language
verbal instructions than written

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

where do drugs come from?

A
chemical modification of a known molecule
random screening of biological products
traditional remedies
rational drug design
natural therapies
luck
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

criteria of successful new drug

A
effective against target protein
no serious ADR's
oral formulation 
good solubility and permeability
scalable manufacture
reasonable half life
good bioavailability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

phases of human drug development

A

pre-clinical, phase 1, 2, 3, and 4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

small subjects to gain information on effectiveness or because of adverse effects

A

phase 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

to determine safety and efficacy in patients with target disorder

A

phase 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

confirmation of efficacy and safety in target disease in a large patient cohort

A

phase 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

estimated 1 to 500 drugs get to this stage

A

phase 4 or post marketing studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ethics board - NHMRC

A
laywomen/man
lawyer
minister of religion
health professional
researcher 
chairperson
How well did you know this?
1
Not at all
2
3
4
5
Perfectly